Literature DB >> 16867263

Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine.

Ming-Xia Wang1, Lei-Ming Ren.   

Abstract

AIM: To study the growth inhibitory and apoptotic effects of adenosine triphosphate (ATP) and adenosine (ADO) on human gastric carcinoma (HGC)-27 cells in vitro and the mechanisms related to the actions of ATP and ADO.
METHODS: MTT assay was used to determine the reduction of cell viability. The morphological changes of HGC-27 cells induced by ATP or ADO were observed under fluorescence light microscope by acridine orange/ethidium bromide double-stained cells. The internucleosomal fragmentation of genomic DNA was detected by agarose gel electrophoresis. The apoptotic rate and cell-cycle analysis after treatment with ATP or ADO was determined by flow cytometry.
RESULTS: ATP, ADO and the intermediate metabolites, ADP and AMP, and the agonist of purinergic receptors, reduced cell viability of HGC-27 cells at doses of 0.3 and 1.0 mmol/L. The distribution of cell cycle phase and proliferation index (PI) value of HGC-27 cells changed when exposed to ATP or ADO at the concentrations of 0.1, 0.3 and 1 mmol/L for 48 h. ATP and ADO both altered the distribution of cell cycle phase via G0/G1- phase arrest and significantly decreased PI value. Under light microscope, the tumor cells exposed to 0.3 mmol/L ATP or ADO displayed morphological changes of apoptosis; a ladder-like pattern of DNA fragmentation obtained from HGC-27 cells treated with 0.1-1 mmol/L ATP or ADO appeared in agarose gel electrophoresis; ATP and ADO induced the apoptosis of HGC-27 cells in a dose-dependent manner at concentrations between 0.03-1 mmol/L. The maximum apoptotic rate of HGC-27 cells exposed to ATP or ADO for 48 h was 13.53% or 15.9%, respectively. HGC-27 cell death induced by ATP or ADO was significantly inhibited by dipyridamole (10 mmol/L), an inhibitor of adenosine transporter, but was not affected by aminophylline, a broad inhibitor of P1 receptors and pyridoxal-phosphate-6-azophenyl-2, 4-disulphonic acid tetrasodium salt (30 micromol/L), a non-selective antagonist of P2 receptors.
CONCLUSION: Extracellular ATP and ADO reduced the cell viability, arrested cell cycle and induced apoptosis in HGC-27 cell line by intracellular uptake of ADO. One of the main routes of ATP-induced apoptosis in HGC-27 cells is through the breakdown to adenosine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867263     DOI: 10.1111/j.1745-7254.2006.00342.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  14 in total

Review 1.  Anticancer effect of adenosine on gastric cancer via diverse signaling pathways.

Authors:  Ayako Tsuchiya; Tomoyuki Nishizaki
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

3.  Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease.

Authors:  Neil V Morgan; Mark R Morris; Hakan Cangul; Diane Gleeson; Anna Straatman-Iwanowska; Nicholas Davies; Stephen Keenan; Shanaz Pasha; Fatimah Rahman; Dean Gentle; Maaike P G Vreeswijk; Peter Devilee; Margaret A Knowles; Serdar Ceylaner; Richard C Trembath; Carlos Dalence; Erol Kismet; Vedat Köseoğlu; Hans-Christoph Rossbach; Paul Gissen; David Tannahill; Eamonn R Maher
Journal:  PLoS Genet       Date:  2010-02-05       Impact factor: 5.917

Review 4.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

Review 5.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

6.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 7.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 8.  The roles of CD73 in cancer.

Authors:  Zhao-wei Gao; Ke Dong; Hui-zhong Zhang
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

9.  MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Authors:  Nathalie Bonnin; Emma Armandy; Julien Carras; Sylvain Ferrandon; Priscillia Battiston-Montagne; Marc Aubry; Sébastien Guihard; David Meyronet; Jean-Philippe Foy; Pierre Saintigny; Sonia Ledrappier; Alain Jung; Ruth Rimokh; Claire Rodriguez-Lafrasse; Delphine Poncet
Journal:  Oncotarget       Date:  2016-07-12

10.  Activation of Nrf2-mediated anti-oxidant genes by antrodin C prevents hyperglycemia-induced senescence and apoptosis in human endothelial cells.

Authors:  Kumar K J Senthil; Vani M Gokila; Sheng-Yang Wang
Journal:  Oncotarget       Date:  2017-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.